Mature data from several phase III randomized controlled trials (NCT02631447 and NCT02224781) would be required to definitively determine optimal systemic therapy sequencing for the management of metastatic BRAF V600-mutant cutaneous melanoma patients. This evidence concerns the gene BRAF and cutaneous melanoma.